Dogwood Therapeutics, Inc. (NASDAQ: DWTX) reported a net loss of $3.8 million for the fourth quarter of 2025 and $35.5 million for the full year, a decline from the $8.2 million Q4 loss and $12.9 million full‑year loss reported for 2024. Research and development expenses rose to $2.3 million in the quarter, while general and administrative costs fell to $1.5 million, a reduction from the $5.2 million spent in 2024 largely due to the elimination of non‑recurring transaction costs associated with the combination with Pharmagesic (Holdings) Inc. in October 2024. Cash and cash equivalents stood at $6.5 million as of December 31, 2025.
The increase in R&D spending reflects the acquisition of in‑process research and development for SP16 and higher costs associated with the Halneuron Phase 2b clinical trial. The company’s R&D budget for 2025 totaled $21.8 million, up from $3.5 million in 2024, underscoring a strategic investment in pipeline advancement despite the continued net loss typical of a development‑stage biopharmaceutical company.
"We have long believed that Nav 1.7 sodium channel inhibition holds great promise for treating both chronic and acute pain. Extrapolation of the current Phase 2b study trends has the potential to represent the first statistically significant trial involving CINP patients under FDA chronic pain study guidance," said CEO Greg Duncan in a December 22, 2025 statement. "The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron® Phase 2b trial," he added on March 18, 2025.
The company plans to use the net proceeds from an $11.4 million equity offering completed in January 2026 to fund operations through the final data readout of the Halneuron Phase 2b trial and into the fourth quarter of 2026. "We plan to utilize the net proceeds from the Offering to advance development of Halneuron® through the ongoing Phase 2b final data readout, while also pursuing strategic opportunities to further strengthen the Company’s research portfolio," Duncan noted in a January 12, 2026 statement.
Dogwood’s focus remains on the Halneuron Phase 2b trial, which has enrolled over 50% of its target cohort and produced a positive interim analysis in a 97‑patient subset. The company expects top‑line data from the trial in the third quarter of 2026, a milestone that will be critical for positioning Halneuron® as the first FDA‑approved therapy for chemotherapy‑induced neuropathic pain, a condition with no current approved treatments.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.